See more : AMCI Acquisition Corp. II (AMCIU) Income Statement Analysis – Financial Results
Complete financial analysis of Genmab A/S (GE9.F) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genmab A/S, a leading company in the None industry within the None sector.
- Lindblad Expeditions Holdings, Inc. (LIND) Income Statement Analysis – Financial Results
- METAWATER Co., Ltd. (9551.T) Income Statement Analysis – Financial Results
- Alpha Technologies Group, Inc. (AHAG) Income Statement Analysis – Financial Results
- Peak Minerals Limited (HEGLF) Income Statement Analysis – Financial Results
- Brickability Group Plc (BRCK.L) Income Statement Analysis – Financial Results
Genmab A/S (GE9.F)
Website: https://www.genmab.com
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 1.94B | 1.14B | 1.36B | 718.10M | 405.38M | 317.70M | 244.25M |
| Cost of Revenue | 74.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.14B | 1.94B | 1.14B | 1.36B | 718.10M | 405.38M | 317.70M | 244.25M |
| Gross Profit Ratio | 96.64% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 997.11M | 716.80M | 538.39M | 394.57M | 301.10M | 180.26M | 108.12M | 83.39M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 424.46M | 343.78M | 162.70M | 82.62M | 45.37M | 28.40M | 19.68M | 13.75M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.42B | 1.06B | 701.09M | 477.20M | 346.47M | 208.67M | 127.80M | 97.15M |
| Cost & Expenses | 1.50B | 1.10B | 734.71M | 510.25M | 365.07M | 220.42M | 134.18M | 102.65M |
| Interest Income | 125.93M | 43.44M | 26.49M | 24.72M | 16.06M | 8.43M | 5.56M | 4.38M |
| Interest Expense | 3.62M | 2.82M | 1.75M | 1.34M | 936.77K | 0.00 | 376.34K | 28.65K |
| Depreciation & Amortization | 43.85M | 38.88M | 33.62M | 33.05M | 18.60M | 11.75M | 6.38M | 5.51M |
| EBITDA | 803.46M | 972.89M | 570.93M | 827.57M | 402.14M | 227.76M | 149.63M | 157.54M |
| EBITDA Ratio | 36.37% | 45.47% | 38.53% | 64.87% | 51.75% | 48.53% | 59.77% | 60.23% |
| Operating Income | 713.60M | 845.38M | 405.81M | 848.13M | 353.03M | 184.96M | 183.52M | 141.60M |
| Operating Income Ratio | 32.30% | 43.47% | 35.58% | 62.44% | 49.16% | 45.63% | 57.76% | 57.97% |
| Total Other Income/Expenses | 42.38M | 85.81M | 129.76M | -54.95M | 29.58M | 31.05M | -40.65M | 10.41M |
| Income Before Tax | 755.98M | 931.19M | 535.57M | 793.18M | 382.60M | 216.01M | 142.87M | 152.00M |
| Income Before Tax Ratio | 34.22% | 47.88% | 46.96% | 58.39% | 53.28% | 53.29% | 44.97% | 62.23% |
| Income Tax Expense | 172.33M | 200.18M | 131.10M | 153.96M | 92.74M | 18.74M | -5.35M | -7.65M |
| Net Income | 583.65M | 731.01M | 404.46M | 639.22M | 289.86M | 197.27M | 148.22M | 159.65M |
| Net Income Ratio | 26.42% | 37.59% | 35.46% | 47.06% | 40.37% | 48.66% | 46.65% | 65.36% |
| EPS | 8.94 | 11.18 | 6.18 | 9.81 | 4.60 | 3.22 | 2.44 | 2.67 |
| EPS Diluted | 8.85 | 11.07 | 6.12 | 9.70 | 4.55 | 3.18 | 2.39 | 2.58 |
| Weighted Avg Shares Out | 65.31M | 65.39M | 65.40M | 65.18M | 62.96M | 61.27M | 60.83M | 59.88M |
| Weighted Avg Shares Out (Dil) | 65.91M | 66.01M | 66.05M | 65.89M | 63.64M | 62.05M | 62.09M | 61.77M |
Source: https://incomestatements.info
Category: Stock Reports